KR970021076A - 약제학적 활성 성분으로서 치환된 2,4-이미다졸리딘디온 화합물 - Google Patents

약제학적 활성 성분으로서 치환된 2,4-이미다졸리딘디온 화합물 Download PDF

Info

Publication number
KR970021076A
KR970021076A KR1019960048441A KR19960048441A KR970021076A KR 970021076 A KR970021076 A KR 970021076A KR 1019960048441 A KR1019960048441 A KR 1019960048441A KR 19960048441 A KR19960048441 A KR 19960048441A KR 970021076 A KR970021076 A KR 970021076A
Authority
KR
South Korea
Prior art keywords
alkyl
formula
compound
substituted
phenyl
Prior art date
Application number
KR1019960048441A
Other languages
English (en)
Other versions
KR100445539B1 (ko
Inventor
마사토시 시모무라
미아키 아사카와
유이치 기타
오스발트 침머
호르스트 뵐케
슈테판 브넨트
코르넬리아 가이스트
카이 츠빈겐베르거
Original Assignee
아이다 겐지
가부시키가이샤 니혼쇼쿠바이
비르츠 프란츠, 파우쓰-베르구스
그뤼넨탈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이다 겐지, 가부시키가이샤 니혼쇼쿠바이, 비르츠 프란츠, 파우쓰-베르구스, 그뤼넨탈 게엠베하 filed Critical 아이다 겐지
Publication of KR970021076A publication Critical patent/KR970021076A/ko
Application granted granted Critical
Publication of KR100445539B1 publication Critical patent/KR100445539B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

본 발명은 2,4-이미다졸리딘디온 화합물, 이의 제조방법 및 약제학적 제제에서의 이들 화합물의 용도에 관한 것이다.

Description

약제학적 활성 성분으로서 치환된 2,4-이미다졸리딘디온 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물.
    상기 화학식에서, R1은 C1-6알킬 또는 C3-6사이클로알킬이고, R2는 C1-6알킬, 페닐, -(CH2)1-3-페닐 또는 -(CH2)1-4-COOR5이거나 R1및 R2가 함께는 -(CH2)4-6-, -(CH2)2-0-(CH2)2- 또는 화학식
    이거나, R3이 H, C1-5알킬 또는 -(CH2)1-4-COOR5이며, R4가 화학식
    의 그룹으로부터 선택된 헤테로방향족 그룹이며, R5는 C1-3알킬이고, R6는 H, C1-4알킬, 페닐 또는 벤질이며, R7은 H, C1-4알킬 또는 트리플루오로메틸이다.
  2. 제1항에 있어서, R1이 C1-4알킬 또는 C3-4사이클로알킬이고, R2가 C3-6알킬, 페닐, -(CH2)1-2-페닐 또는 -(CH2)1-2-COOR5이거나, R1및 R2가 함께는 -(CH2)5- 또는 화학식
    이고, R3이 H, C1-4알킬 또는 -(CH2)1-2-COOR5이며, R4가 화학식
    의 그룹으로부터 선택된 헤테로방향족 그룹이며, R5가 C1-3알킬이고, R6이 H 또는 페닐이며, R7이 H, 메틸, 3급 부틸 또는 트리플루오로메틸임을 특징으로 하는, 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물.
  3. 제1항 또는 제2항에 있어서, R1이 에틸 또는 사이클로부틸이고, R2가 페닐이거나, R1및 R2가 함께는 -(CH2)5-임을 특징으로 하는, 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, R1및 R2가 함께 -(CH2)5-임을 특징으로 하는, 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, R3이 H, C1-3알킬 또는 -CH2-COOR5이고, R5가 에틸임을 특징으로 하는, 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물.
  6. 제5항에 있어서, R3이 H임을 특징으로 하는, 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물.
  7. 제1항 내지 제6항중 어느 한 항에 있어서, R4가 피리딘-4-일, 피리딘-3일, 티아졸-2-일, 3-메틸이속사졸-5-일 또는 5-메틸이속사졸-3-일임을 특징으로 하는, 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물.
  8. 제7항에 있어서, R4가 티아졸-2-일임을 특징으로 하는, 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물.
  9. 화학식 (2)의 아민이 1,1′-카보닐디이미다졸 또는 디페닐 카보네이트를 가한 후 화학식 (3)의 화합물과 반응시켜 R3이 H인 화학식 (1)의 화합물을 수득하고, 경우에 따라, 이 화합물을 탈양자화한 후 화학식 (4)의 화합물 또는 화학식 (5)의 화합물과 반응시켜 R3이 C1-5알킬 또는 -(CH2)1-4-COOR5인 화학식 (1)의 화합물을 수득함을 특징으로 하는, 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물의 제조 방법.
    상기 화학식에서, R1은 C1-6알킬 또는 C3-6사이클로알킬이고, R2는 C1-6알킬, 페닐, -(CH2)1-3-페닐 또는 -(CH2)1-4-COOR5이거나 R1및 R2가 함께는 -(CH2)4-6-, -(CH2)2-0-(CH2)2- 또는 화학식
    이거나, R3은 H, C1-5알킬 또는 -(CH2)1-4-COOR5이고, R4는 화학식
    의 그룹으로부터 선택된 헤테로방향족 그룹이며, R5는 C1-3알킬이고, R6는 H, C1-4알킬, 페닐 또는 벤질이며, R7은 H, C1-4알킬 또는 트리플루오로메틸이고, R8은 H 또는 C1-3알킬이며, X는 Cl, Br 또는 I이다.
  10. 약제학적 제제중 활성 성분으로서의, 제1항에 다른 화학식 (1)의 치환된 2,4-이미다졸리딘디온 화합물의 용도.
  11. 제10항에 있어서, 약제학적 제제가 면역조절제임을 특징으로 하는 용도.
  12. 제10항에 있어서, 약제학적 제제가 항맥관염 작용을 갖는 것을 특징으로 하는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960048441A 1995-10-27 1996-10-25 치환된2,4-이미다졸리딘디온화합물및이를함유하는약제학적조성물 KR100445539B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19540027.5 1995-10-27
DE19540027A DE19540027A1 (de) 1995-10-27 1995-10-27 Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
JP7-283270 1995-10-31

Publications (2)

Publication Number Publication Date
KR970021076A true KR970021076A (ko) 1997-05-28
KR100445539B1 KR100445539B1 (ko) 2004-12-30

Family

ID=7775931

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960048441A KR100445539B1 (ko) 1995-10-27 1996-10-25 치환된2,4-이미다졸리딘디온화합물및이를함유하는약제학적조성물

Country Status (23)

Country Link
US (1) US6004963A (ko)
EP (1) EP0770613B1 (ko)
JP (1) JPH09188677A (ko)
KR (1) KR100445539B1 (ko)
CN (1) CN1097050C (ko)
AR (1) AR004517A1 (ko)
AT (1) ATE181072T1 (ko)
AU (1) AU707751B2 (ko)
CA (1) CA2188908A1 (ko)
CO (1) CO4750655A1 (ko)
DE (2) DE19540027A1 (ko)
DK (1) DK0770613T3 (ko)
ES (1) ES2135148T3 (ko)
GR (1) GR3030558T3 (ko)
HK (1) HK1010367A1 (ko)
HU (1) HU222120B1 (ko)
IL (1) IL119488A (ko)
MX (1) MX9605023A (ko)
PE (1) PE20011055A1 (ko)
PL (1) PL184446B1 (ko)
RU (1) RU2163603C2 (ko)
SI (1) SI0770613T1 (ko)
ZA (1) ZA968956B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
DE19917961A1 (de) 1999-04-21 2000-10-26 Degussa Verfahren zur Herstellung von Aminosäurederivaten
WO2001007048A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
ES2284641T3 (es) 2000-05-31 2007-11-16 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion celular mediada por alfa-l-beta-2.
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
FR2896504B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AU2012241184B2 (en) * 2006-03-27 2016-01-07 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP3412290B1 (en) * 2006-03-27 2021-03-03 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
CN101460467B (zh) * 2006-03-29 2012-09-19 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
WO2008021309A1 (en) * 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
US7649007B2 (en) * 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
CA2661315C (en) * 2006-09-08 2015-11-24 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
SG192439A1 (en) * 2008-06-27 2013-08-30 Novartis Ag Organic compounds
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091596B1 (de) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
US4746669A (en) * 1985-12-23 1988-05-24 Merck & Co., Inc. Substituted thiazoles as immunoregulants
JPH02101065A (ja) * 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
EP0557408A4 (en) * 1990-11-06 1993-10-27 Smith-Kline Beecham Corporation Imidazolidinone compounds
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US7466669B2 (en) * 2003-11-14 2008-12-16 Telefonaktiebolaget Lm Ericsson (Publ) Reverse link scheduler for CDMA networks

Also Published As

Publication number Publication date
CO4750655A1 (es) 1999-03-31
HU222120B1 (hu) 2003-04-28
KR100445539B1 (ko) 2004-12-30
EP0770613A1 (de) 1997-05-02
ZA968956B (en) 1997-05-29
IL119488A0 (en) 1997-01-10
IL119488A (en) 2001-01-11
HK1010367A1 (en) 1999-06-17
DE19540027A1 (de) 1997-04-30
SI0770613T1 (en) 1999-10-31
MX9605023A (es) 1997-06-28
HUP9602932A3 (en) 1998-08-28
CN1152573A (zh) 1997-06-25
ATE181072T1 (de) 1999-06-15
AR004517A1 (es) 1998-12-16
AU707751B2 (en) 1999-07-22
EP0770613B1 (de) 1999-06-09
RU2163603C2 (ru) 2001-02-27
CN1097050C (zh) 2002-12-25
AU6818196A (en) 1997-05-01
GR3030558T3 (en) 1999-10-29
DE59602155D1 (de) 1999-07-15
PL316706A1 (en) 1997-04-28
ES2135148T3 (es) 1999-10-16
PL184446B1 (pl) 2002-10-31
HU9602932D0 (en) 1996-12-30
DK0770613T3 (da) 1999-12-13
CA2188908A1 (en) 1997-04-28
HUP9602932A2 (hu) 1998-07-28
PE20011055A1 (es) 2001-12-29
JPH09188677A (ja) 1997-07-22
US6004963A (en) 1999-12-21

Similar Documents

Publication Publication Date Title
KR970021076A (ko) 약제학적 활성 성분으로서 치환된 2,4-이미다졸리딘디온 화합물
ITRM920361A0 (it) Composizioni farmaceutiche contenenti un composto allilamminico quale principio attivo.
KR950007850A (ko) 항균물질 및 항궤양물질 포함 제제
KR900016220A (ko) 매크로리드 조성물
KR900018098A (ko) 피리돈 카르복실산과 항균제
WO2001009103A3 (en) Imidazole antiproliferative agents
DE59009074D1 (de) Diarylsubstituierte heterocyclische Verbindung, ihre Herstellung und Arzneimittel und Kosmetika daraus.
SE8204237L (sv) Karbostyrilforeningar, kompositioner innehallande dessa samt forfaranden for framstellning derav
KR900015721A (ko) 신규 방법 및 화합물들
SE8700113D0 (sv) An oil-in-water pesticidal emulsion
EP0327709A3 (en) Novel platinum complex, antineoplastic agent containing the same, intermediate therefor, preparation method and use
LV10949A (lv) Aizvietoti 4-fenil-4piperidinkarboksamidi to iegusanas panemiens farmaceitiska kompozicija
JPS52136118A (en) Modification of bestatin and analogous compounds and their preparation
EP0387070A3 (en) N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
FI933719A0 (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
DE69330601D1 (de) Serotoninergische ergolin derivate
WO2004055009A8 (en) Novel compounds having selective inhibiting efect at gsk3
KR900701262A (ko) 췌장염 등에 대한 치료제
RU2003122785A (ru) 9a-n-[n`-(фенилсульфонил)карбамоил)-производные 9-дезоксо-9-дигидро-9a-аза-9a-гомоэритромицина a и 5-o-дезозаминил-9-дезоксо-9-дигидро-9a-аза-9a-гомоэритронолида a
NO176018C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive S-enantiomerer av substituerte 2-aminotetraliner
KR870011095A (ko) 5위가 황으로 치환된 피리딘 모노카르복시 제초제
MX9206930A (es) Nuevos compuestos
JPS57120502A (en) Insecticide
RU94036762A (ru) Гетероарилпиперидины, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция
JPS53127415A (en) N-((methylphosphino)methyl) herbicide containing the compound as effective component

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20070808

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee